Market Chameleon (Fri, 20-Mar 7:19 AM ET)
Solid Bio wins new Buy at Guggenheim on lead asset
Seeking Alpha News (Fri, 20-Mar 10:24 AM ET)
TipRanks (Thu, 19-Mar 3:10 PM ET)
Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Sarepta Therapeutics (SRPT)
TipRanks (Thu, 19-Mar 11:20 AM ET)
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and LivaNova (LIVN)
TipRanks (Thu, 19-Mar 11:00 AM ET)
Sarepta to soon submit sNDAs for traditional approval for Duchenne treatments
Seeking Alpha News (Thu, 19-Mar 10:13 AM ET)
Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53
Business Wire (Thu, 19-Mar 8:30 AM ET)
Business Wire (Mon, 16-Mar 8:33 AM ET)
Business Wire (Fri, 27-Feb 9:00 AM ET)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of March 23, 2026, SRPT stock price climbed to $17.71 with 2,741,061 million shares trading.
SRPT has a beta of 1.64, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.05 to the broad based SPY ETF.
SRPT has a market cap of $1.86 billion. This is considered a Small Cap stock.
Last quarter Sarepta Therapeutics reported $443 million in Revenue and -$3.58 earnings per share. This beat revenue expectation by $45 million and missed earnings estimates by -$2.71.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJR, FBT, VTI, XBI, VB.
SRPT has underperformed the market in the last year with a return of -75.9%, while the SPY ETF gained +17.9%. In the last 3 month period, SRPT fell short of the market, returning -15.8%, while SPY returned -3.4%. However, in the most recent 2 weeks SRPT has outperformed the stock market by returning +6.0%, while SPY returned -2.3%.
SRPT support price is $16.09 and resistance is $17.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.
